Savara
SVRA5.3300.00% ( 0.000 )
Savara (SVRA)
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company’s lead product candidate is molg...
- Open
- 5.340
- High
- 5.370
- Low
- 5.180
- Prev. Close
- 5.330
- Volume
- 795.28K
- Turnover
- 4.20M
- Avg Price
- 5.277
- Bid/Ask Ratio
- --
- Amplitude
- 3.56%
- 52wk High
- 7.005
- Volume Ratio
- 0.36
- Turnover Ratio
- 0.98%
Savara Analyst Rating
View MoreForecast & Rating
Jul 22, 2026Price forecast
$10.94105.21%
Forecast & RatingStrong buy
8analysts
- Strong buy75.00%
- Buy25.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Jul 15 at 11:52 AM
Savara posts corporate presentation focused on autoimmune pulmonary alveolar proteinosis and MOLBREEVI program
- Simplywall · Jul 8 at 07:18 AM
Savara (SVRA) Stock May Trade At A Premium On Pipeline Expectations
- Simplywall · Jun 29 at 02:50 PM
Does FDA Review of MOLBREEVI and Insider Sales Shift the Bull Case For Savara (SVRA)?
- Simplywall · Jun 28 at 11:04 AM
Is Savara (SVRA) Expensive As Its Rally Puts A Premium On Book Value?
- PUBT · Jun 22 at 07:18 PM
Savara CFO David Lowrance disposes of 580,187 common shares worth $3.31 million
- StockTitan · Jun 12 at 07:05 AM
Savara Announces New Employment Inducement Grant | SVRA Stock News
